MG
PRNB

Michael Gelband’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Michael Gelband’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,177
Closed -$550K – 1433
2019
Q1 		$550K Buy
+16,177
New +$514K 0.04% 305

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Michael Gelband's PRNB Position: Q2 2019 in Review

Michael Gelband sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q2 2019, closing a stake of 16,177 shares — an estimated $550K sold.

Michael Gelband first reported a position in PRNB in Q1 2019 and held it in 1 quarter. The position peaked at $550K in Q1 2019. 74 funds tracked by Wall St. Rank hold PRNB as of Q2 2019.

  • Michael Gelband reported no remaining Principia Biopharma Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Michael Gelband sold 16,177 Principia Biopharma Inc. Common Stock shares in Q2 2019, an estimated $550K.
  • Michael Gelband first reported a position in Principia Biopharma Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Michael Gelband's Principia Biopharma Inc. Common Stock position peaked at $550K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q2 2019.

Based on ExodusPoint Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.